Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration

American Journal of Health-System Pharmacy

Volumn 65, Issue 18, 2008, Pages 1735-1739

  Kupiec, Thomas C ^a   Trusley, Craig ^b   Ben, Michel ^a   Trissel, Lawrence A ^c  

^a Analytical Research Laboratories   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TriPharma Research   (United States)

Author keywords

Anesthetics, local; Anticoagulants; Antiemetics; Atropine sulfate; Concentration; Dextrose; Diluents; Electrolytes; Famotidine; Gastrointestinal drugs; Heparin sodium; Incompatibilities; Injections; Lidocaine hydrochloride; Palonosetron hydrochloride

Indexed keywords

ATROPINE; FAMOTIDINE; GLASS; GLUCOSE; HEPARIN; LIDOCAINE; PALONOSETRON; POLYPROPYLENE; POTASSIUM CHLORIDE;

ARTICLE; COLOR; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION SELECTIVE ELECTRODE; PARTICLE SIZE; POTENTIOMETRY; PRIORITY JOURNAL; SIMULATION; TURBIDITY;

EID: 52949120338     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070293     Document Type: Article

References (27)

1. Aloxi (palonosetron hydrochloride package insert). Bloomington, MN: MGI Pharma, Inc.; 2006 Jan.
2. Siddiqui MA, Scott LJ. Palonosetron. Drugs. 2004; 64:1125-32.
3. Rubenstein EB. Palonosetron: a unique 5-HT(3) receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Heamotol Oncol. 2004; 2:284-8.
4. Eglen RM, Lee CH, Smith WL et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol. 1995; 114:860-6.
5. Candiotti KA, Kovac AL, Melson TI et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. In press.
6. Kovac AL, Eberhart L, Kotarski J et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. In press.
7. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann Pharmacother. 2004; 38:1608-11.
8. Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J Oncol Pharm Pract. 2004; 10:191-5.
9. Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacother. 2005; 39:280-3.
10. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl with topotecan HCl and irinotecan HCl during simulated Y-site administration. Int J Pharm Compound. 2005; 9:238-41.
11. Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron HCl with lorazepam and midazolam HCl during simulated Y-site administration. Int J Pharm Compound. 2005; 9:235-7.
12. Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound. 2005; 9:320-2.
13. Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am J Health-Syst Pharm. 2005; 62:1998-2000.
14. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron HCl with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound. 2006; 10:234-6.
15. Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am J Health-Syst Pharm. 2004; 61:1596-8.
16. Ben M, Trusley C, Kupiec TC et al. Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated Y-site administration. Int J Pharm Compound. 2007; 11:82-5.
17. Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five narcotics during simulated Y-site administration. Am J Health-Syst Pharm. 2007; 64:1209-13.
18. Trusley C, Ben M, Kupiec TC et al. Palonosetron physical and chemical stability with metoclopramide and promethazine during simulated Y-site administration. Int J Pharm Compound. 2007; 11:82-5.
19. Trusley C, Ben M, Kupiec TC et al. Palonosetron physical and chemical stability with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound. 2008; 12:156-60.
20. Ben M, Trusley C, Kupiec TC et al. Palonosetron physical and chemical stability with three β-lactam antibiotics during simulated Y-site administration. Int J Pharm Compound. 2007; 11:520-4.
21. Kupiec TC, Ben M, Trusley C et al. Palonosetron physical and chemical stability with gentamicin, metronidazole, and vancomycin during simulated Y-site administration. Int J Pharm Compound. 2008; 12:170-3.
22. Allen LV Jr, Levinson RS, Phisutsinthrop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.
23. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992; 49:1716-9.
24. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm. 1993; 50:300-4.
25. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1993; 50:2359-63.
26. Palonosetron HCl i.v. injection 0.05 mg/mL and 0.15 mg/mL end-product test procedure. Minneapolis: MGI Pharma, Inc., undated.
27. Gupta VD, Stewart KR. Chemical stabilities of lignocaine hydrochloride and phenylephrine hydrochloride in aqueous solution. J Clin Hosp Pharm. 1986; 11:449-52.